Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

Journal of Infection

Volumn 65, Issue 4, 2012, Pages 326-335

  Caseiro, Marcos M ^a   Nelson, Mark ^b   Diaz, Ricardo S ^c   Gathe, Joseph ^d   de Andrade Neto, Jose L ^e   Slim, Jihad ^f   Solano, Antonio ^g   Netto, Eduardo M ^h   Mak, Carmen ⁱ   Shen, Junwa ^j   Greaves, Wayne ⁱ   Dunkle, Lisa M ⁱ   Vilchez, Regis A ⁱ   Zeinecker, Jennifer ^j  

^a Guilherme Álvaro Hospital   (Brazil)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Therapeutic Concepts   (United States)

^e PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^f ST MICHAEL S MEDICAL CENTER   (United States)

^g Hospital Calderon Guardia   (Costa Rica)

^h FEDERAL UNIVERSITY OF BAHIA   (Brazil)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j University of Town   (South Africa)

more..

Author keywords

CCR5 antagonist; HIV 1; Treatment experienced patients; Vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; ENFUVIRTIDE; PLACEBO; RALTEGRAVIR; VICRIVIROC; VIRUS RNA;

ADULT; ARTICLE; BACKACHE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL CARCINOMA; GENOTYPE; HEART INFARCTION; HEMOPTYSIS; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLUENZA; INSOMNIA; LIVER INJURY; LIVER METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEIZURE; SENSITIVITY ANALYSIS; SEPSIS; STOMACH TUMOR; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; VIRAL TROPISM; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLACEBOS; PYRIMIDINES; RECEPTORS, CCR5; RECEPTORS, HIV; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 84865985400     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.05.008     Document Type: Article

References (16)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents March 27, 2012, US Department of Health and Human Services, Bethesda, MD, 1-239.
2. Thompson M.A., Aberg J.A., Cahn P., Montaner JS., Rizzardini G., Telenti A., et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321-333. International AIDS Society-USA.
3. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359(4):355-365. BENCHMRK Study Teams.
4. Picchio G., Vingerhoets J., Tambuyzer L., Coakley E., Haddad M., Witek J. Prevalence of susceptibility to etravirine by genotype and phenotype in samples received for routine HIV-1 resistance testing in the United States. AIDS Res Hum Retroviruses Published Online June 11, 2011.
5. Poveda E., de Mendoza C., Martin-Carbonero L., Corral A., Briz V., González-Lahoz J., et al. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 2007, 60(4):885-888.
6. Strizki J.M., Tremblay C., Xu S., Wojcik L., Wagner N., Gonsiorek W., et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005, 49(12):4911-4919.
7. Suleiman J., Zingman B.S., Diaz R.S., Madruga JV., DeJesus E., Slim J., et al. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis 2010, 201(4):590-599.
8. Gulick R.M., Su Z., Flexner C., Hughes MD., Skolnik PR., Wilkin TJ., et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis 2007, 196(2):304-312.
9. Grinsztejn B., Nguyen B.Y., Katlama C., Gatell JM., Lazzarin A., Vittecoq D., et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369(9569):1261-1269. Protocol 005 Team.
10. Reeves J.D., Coakley E., Petropolous C.J., Whitcomb J.M. An enhanced-sensitivity trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: a review of analytical and clinical studies. J Viral Entry 2009, 3:94-102.
11. Hammer S.M., Saag M.S., Schechter M., Montaner JS., Schooley RT., Jacobsen DM., et al. International AIDS Society-USA panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006, 296(7):827-843.
12. Division of AIDS Table for Grading Severity of Adverse Events. 2004.
13. Gulick R.M., Lalezari J., Goodrich J., Clumeck N., DeJesus E., Horban A., et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008, 359(14):1429-1441. MOTIVATE Study Teams.
14. Fatkenheuer G., Nelson M., Lazzarin A., Konourina I., Hoepelman AI., Lampiris H., et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008, 359(14):1442-1455. MOTIVATE 1 and MOTIVATE 2 Study TEAMS.
15. Mani N., Murray J., Gulick R.M., Josephson F., Miller V., Miele P., et al. Novel clinical trial designs for the development of new antiviral agents. AIDS 2012, 10.1097/QAD.0b013e3283519371.
16. Vilchez RA. Novel clinical trial designs and HIV-1 RNA assessments with end-point and real-time PCR tests. AIDS, doi:10.1097/QAD.0b013e328550dc8.